Azenta Inc (AZTA)vsResMed Inc (RMD)
AZTA
Azenta Inc
$21.86
+2.58%
HEALTHCARE · Cap: $1.01B
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 807% more annual revenue ($5.40B vs $595.03M). RMD leads profitability with a 27.5% profit margin vs -10.1%. AZTA appears more attractively valued with a PEG of 0.53. RMD earns a higher WallStSmart Score of 70/100 (B).
AZTA
Buy57
out of 100
Grade: C
RMD
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-12.2%
Fair Value
$27.14
Current Price
$21.86
$5.28 premium
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 80.0% year-over-year
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 1.5% — below average capital efficiency
Currently unprofitable
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 80.0% demonstrates continued momentum. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : AZTA
The primary concerns for AZTA are P/E Ratio, Market Cap, Return on Equity.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
AZTA profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.40 — expect wider price swings.
AZTA is growing revenue faster at 80.0% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 57/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a leading provider of sample management solutions and life science tools, specializing in enhancing laboratory efficiencies for the biotechnology and pharmaceutical sectors. Leveraging innovative automated solutions, biorepository services, and advanced storage technologies, the company empowers clients to accelerate drug discovery while maintaining strict regulatory compliance. With a strong focus on cutting-edge technology and collaborative partnerships, Azenta is strategically positioned to capitalize on growth opportunities within the expanding global life sciences market. Its unwavering commitment to advancing scientific research through sophisticated products further reinforces its competitive edge in biobanking and sample management.
Visit Website →ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?